Technology

TECHNOLOGY

Barinthus Biotherapeutics has a powerful suite of innovative technologies to create more effective immunotherapies for the treatment of infectious diseases, cancer and autoimmunity.

Our proprietary platforms, ChAdOx, MVA, and SNAP, are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. This is achieved through increasing disease specific CD8 T cell activity in the case of infectious diseases and cancers, or dampening CD4 and CD8 T cells, and increasing T Regulatory cells in autoimmunity.

OUR PLATFORMS

Viral Vector Platforms

ChAdOx1 (Chimpanzee Adenovirus Oxford) and ChAdOx2 are modified, replication-incompetent simian adenoviral vectors. Modified Vaccinia Ankara (MVA) is a well-studied, attenuated Vaccinia virus. Both vectors encode the target antigen.
Immunisation with ChAdOx potently primes T cells against the target antigen. A second immunisation with MVA boosts and expands the T cell response against the target antigen.

This approach reproducibly achieves immune responses that are differentiated by their high magnitude, high quality, and highly durable antigen-specific CD4+ helper and CD8+ cytotoxic T cells. These characteristics are ideal for immunotherapies designed to treat infectious disease and cancer.

Viral Vector Platforms

SNAP-Tolerance Immunotherapy (TI)

This fully synthetic and biocompatible platform utilizes self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition for inducing the specific T cell populations needed for diverse therapeutic indications across autoimmunity.

SNAP-TI